Genetics of warfarin dosing - One polymorphism at a time

The Lancet

Volumn 382, Issue 9894, 2013, Pages 749-751

  Alberts, Mark J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

AFRICAN AMERICAN; DRUG METABOLISM; FOOD; FOOD DRUG INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INTERNATIONAL NORMALIZED RATIO; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84883134060     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60942-3     Document Type: Note

References (15)

1. Newman DH, Zhitomirsky I. The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department. Ann Emerg Med 2006; 48: 182-89.
2. Tan GM, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 2010; 11: 439-48.
3. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharm Therapeut 2001; 70: 159-64.
4. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Engl J Med 2005; 352: 2285-93.
5. Mlynarsky L, Bejarano-Achache I, Muszkat M, Caraco Y. Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 1/1 carriers. Eur J Clin Pharm 2012; 68: 617-27.
6. Nakamura K, Obayashi K, Araki T, et al. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Pharm Therapeut 2012; 37: 481-85.
7. Lane S, Al-Zubiedi S, Hatch E, et al. The population pharmacokinetics of R- and S-warfarin: Effect of genetic and clinical factors. Brit J Clin Pharm 2012; 73: 66-76.
8. Limdi NA, Beasley TM, Crowley MR, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 2008; 9: 1445-58.
9. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement - a systematic review and meta analysis. Thromb Res 2010; 125: e159-66.
10. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharm Therapeut 2010; 87: 445-51.
11. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 2013; published online June 5. http://dx.doi.org/10.1016/ S0140-6736(13)60681-9.
12. Ott J. Association of genetic loci: replication or not, that is the question. Neurology 2004; 63: 955-58.
13. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-09.
14. Thompson CA. FDA encourages genetics-aided warfarin dosing. Am J Health Syst Pharm 2007; 64: 1994-96.
15. Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J 2011; 32: 1968-76.